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Both ultraviolet B (UVB) exposure and bathing have been recognised to have beneficial
effects on several chronic skin diseases.
1,2 Most types of psoriasis are thought to respond to
such interventions. In particular, the combination of baths in an established saline solution
and exposure to ultraviolet rays of a wave-length of 311 nm seems to be effective
particularly in the treatment of psoriasis.
3,4 The efficacy of this method is not completely
due to improved effect of phototherapy following hydration of the cornified layer, but also
to the ionic mechanism of the elements contained in the baths.
5 Several studies have tested
different spa water baths, however only a few are randomised controlled trials, never-
theless, the majority of these studies observed the positive effect of saline waters.
6,7
Comano, located in Northern Italy, has been known as an important spa water centre
since ancient times. The water is oligometallic, has a temperature of 27˚C at the springs,
and a pH of 7.5-7.6.
8 The Italian National Health System officially recognises the
beneficial effects of spa water treatment alone or in conjunction with treatments such as
UVB treatment for psoriasis. We designed an observational study as a first step to evaluate
the effect of Comano’s water baths alone or in association with phototherapy on psoriasis
patients, both in terms of clinical severity and patient’s quality of life (QoL).
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after therapy in SAPASI_50 score was reached by 42% and 37% of patients in the BPT and BT groups, respectively. At
follow-up, both groups had better scores on all SF-36 scales (with statistically significant improvement in social functioning
and mental health in the BPT group) and in all Skindex-29 scales. A statistically significant reduction of GHQ-12 positive
cases was observed in the BPT group. Conclusion: Comano spa-water alone or in combination with phototherapy had
beneficial therapeutic effects on patients with psoriasis. Although our observational study design prevents us from making
meaningful comparisons between the 2 interventions, the combination of balneo and phototherapy seems to improve QoL
and lessen clinical severity, and reduced the proportion of GHQ-12 positive cases.
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from September to November 2005. No patient concurrently
undergoing any other active treatment for psoriasis was
enrolled in the study, and patients who were willing to enter the
study protocol voluntarily stopped any treatment before starting
the intervention. Only topical emollients for psoriasis treatment
were allowed for the 2-month period after the bath sessions.
Other inclusion criteria were: 18 years of age or older, body
surface area involved ≥ 10% (i.e., moderate-severe chronic
plaque psoriasis), and patients signed a written informed
consent form. Patients with erythrodermic and pustular forms
of psoriasis, including palmoplantar types, as well as patients
who had contraindications to phototherapy or balneotherapy
were excluded from the study. The study was approved by the
Ethical Committee of IDI-IRCCS.
Patients who agreed to participate in the study underwent 1
of the 2 following treatment programs:
A) Two weeks of daily balneotherapy with Comano water
followed by UVB 311-nm phototherapy (BPT)
B) Two weeks of daily bath treatments with Comano water
alone (BT).
The choice of treatment was agreed between patient and
physician after a briefing.
The treatment included 12 to 14 total immersion baths for 20
minutes once a day. The detailed characteristics of Comano
water are described in Table 1. Exposure to Narrow Band UVB
was determined and monitored according to skin type, and was
carried out within 15 minutes from the end of the bath. 
The severity of disease was assessed by a dermatologist who
explained the purposes of the study to patients and gave them
questionnaires to complete. The dermatologist monitored
patients at the beginning of the study, during therapy, and 2
months later, when the follow-up questionnaires were collected.
The dermatologist also collected information on socio-
demographic variables, clinical history, and other factors of
clinical interest (e.g. clinical type and location of the disease,
personal and family history of psoriasis and other diseases,
seasonal changes, symptoms, etc.).
The self-administered Psoriasis Area Severity Index (SAPASI),
the Skindex-29, the 36-item Short Form of the Medical
Outcomes Study questionnaire (SF-36), and the General Health
Questionnaire (GHQ)-12 were administered to patients before
any study treatment was started. After 2 months from the end of
BT or BPT, a follow up with SAPASI, GHQ-12 and Skindex-
29 was requested and obtained by mail. 
SAPASI is a structured instrument consisting of a line-
drawing silhouette of the front and back of a body for patients
to shade-in the affected areas and of 3 visual analog scales for
recording the erythema, induration and scaliness of an average
lesion. Based on the silhouette shading, 2 of the authors
estimated the proportion of involved area for each body district,
using the body surface as denominator. Disagreements were
discussed until a consensus on the estimated proportion was
reached. Finally, the area of psoriatic involvement for each of
the 4 regions was assigned a numerical value of 0-6
corresponding to 0-100% involvement: 0, no involvement; 1, <
10%; 2, 10 < 30%; 3, 30 < 50%; 4, 50 < 70%; 5, 70 < 90%; 6,
90-100%. For each region, erythema, desquamation and
induration of the plaques were rated according to the classical
five-point scale: 0, no involvement; 1, slight; 2, moderate; 3,
marked; 4, very marked.
The SAPASI scores were then calculated by investigators
using electronic spreadsheets to implement the formulas
originally proposed.
9 Such scores have the same range of PASI
scores and have been shown to have a high correlation with
them.
10 After 2 months, a SAPASI reduction of at least 50%
(SAPASI_50) was considered to be a successful clinical
outcome. 
The Skindex-29 is a reliable and valid instrument that has
been specifically designed for measuring health-related QoL in
dermatological patients.
11 It is constituted by 3 scales assessing
areas considered essential in any instrument purported to assess
QoL: burden of symptoms, functioning, and emotional state.
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MATERIALS AND METHODS
Table 1.Physical and Chemical Features of Comano Spa Water
Temperature of the water at the spring 27.7 ˚C
pH 7.2
Dry sediment  180˚C 190 mg/L
NH3 + 0.015 mg/L
No3
- 0.30 mg/L
PO4
- - - 0.03 mg/L
Carbon dioxide 3.85 mL
Oxigen 3.08 mL
Na + 2.0 mg
K + 0.5 mg
Mg ++ 12.16 mg
Ca ++ 48.90 mg
HCO3 196.56 mg
Cl - 0.80 mg
SO4 6.90 mg
SiO2 4.90 mg
F 
- 0.43 mg
Lithium 0.0006 mg
Aluminium 0.032 mg
Manganese 0.0016 mg
Iron 0.010 mg
Copper 0.005 mg
Zinc 0.043 mg
Stronthium 0.23 mg
Radioactivity (Radon)              picocurie/I 229U.M./I 0.75The Italian version of this self-administered questionnaire has
recently been validated.
12,13 Patients answered the 29 questions
referring to the previous 4-week period on a 5-point scale from
‘never’ (= 0) to ‘all the time’ (= 4). The score of each scale
ranges from 0 to 100 (as a percentage of the maximum score
obtainable on that scale), and higher scores reflect a worse
QoL.
In addition, we also analysed what we called “warnings” in
the Skindex-29; i.e. items/symptoms that the patient answered
having experienced “all the time” in the four weeks before
completing the questionnaire.
The SF-36 questionnaire was designed as a generic indicator
of health status for use in population surveys and evaluative
studies of health policy.
14 As a generic instrument, the SF-36
was designed to be applicable to a wide range of types and
severity of conditions. It is a useful instrument for monitoring
patients with multiple conditions, for comparing the health
status of patients with different conditions, and for comparing
patients to the general population. The SF-36 includes 36 items,
in a Likert-type or forced-choice format, intended to measure
the following 8 dimensions: physical functioning (PF,
limitations in performing physical activities such as bathing or
dressing), role-physical (RP, limitations with work and other
daily activities as a result of physical health), bodily pain (BP,
how severe and limiting is pain), general health (GH, how
general personal health is evaluated by the patient), vitality
(VT, feeling tired and worn out vs. feeling full of energy),
social functioning (SF, interference with normal social activities
due to physical or emotional problems), role-emotional (RE,
limitations with work and other daily activities as a result of
emotional problems), mental health (MH, feeling nervous and
depressed vs. peaceful, happy and calm). Scores for each domain
range from 0 to 100, with high scores indicating a better status.
We used the Italian version of the SF-36 cross-culturally
validated within the framework of the International Quality of
Life Assessment (IQOLA) Project.
The GHQ-12 is a self-administered questionnaire consisting
of 12 items, designed to measure psychological distress and to
detect current non-psychotic psychiatric disorders, usually
depressive or anxiety disorders. The reliability and validity of
the Italian version have been documented in many types of
patients, including those with dermatological conditions.
15,16
Answers are given on a 4-point scale. For instance, the answers
to the item “in the last weeks, did you feel under strain?” are
“no”, “no more than usual”, “more than usual”, and “much
more than usual”. When scored with the binary method (0-0-1-
1), the GHQ-12 can be used as a screening tool to detect minor
non-psychotic psychiatric disorders. For instance, to receive a
score of 1 on the previously described item, a subject should
answer “more than usual” or “much more than usual”. In this
way, each subject obtains a score from 0 to 12, based on a
previous validation study operationally, patients scoring four or
more were considered as “GHQ-12 positive”.
17
Within-patient comparisons (baseline vs. two months follow-
up) were performed using the paired Student’s t-test for non-
independent observations. The Student’s t-test for independent
samples was used to compare the 2 treatment groups in each of
questionnaires score/scales/determinants. 
Two separate logistic regression models (for BPT and BT,
respectively) were created to see whether SAPASI improvement
at 2-month follow-up was associated with BPT or BT treatment
while simultaneously controlling for other relevant variables
such as age, gender, cigarette smoking, alcohol consumption,
duration of disease, baseline level of clinical severity, and
baseline presence of GHQ-12 positivity. 
All statistical analyses were performed using the statistical
software Stata 9.0 for Windows.
Patient characteristics at baseline are summarized in Table 2.
Briefly, there were 66 patients in the BPT group, while there
were 45 patients in BT group. Patients in BPT were younger
(45 ± 13 years) than in BT (55 ± 15). At baseline, BPT patients
had better SF-36 scores on the PF and PR scales, than BT
patients. GHQ-12 cases were 32% in the BPT group and 22%
in the BT group. SAPASI scores at baseline were significantly
lower in BT than BPT. The patients in BPT, depending on the
phototype, started UVB treatment with  0.02j and reached  a
mean cumulative dose of 12.64j.
Fifty four patients (82%) in BPT and 38 (84%) in BT sent
back the questionnaires by mail 2 months after the end of the
Comano treatment. No undesired side effects were described.
The mean SAPASI scores were significantly reduced at 2-
month follow-up in both treatment groups (15.2 to 8.7 in group
BPT and 11.6 to 7.8 in group BT). The mean value of SAPASI
percent reduction was 39.5% in BPT and 37% in BT. SAPASI-
50 was reached by 42% and 37% of patients in the BPT and BT
groups, respectively.
When the 2 separate logistic regression models for BPT and
BT were created, none of the simultaneously considered
variables (i.e., age, gender, cigarette smoking, alcohol consump-
tion, duration of disease, baseline level of clinical severity, and
baseline presence of GHQ-12 positivity) in addition to
treatment resulted to be associated with SAPASI reduction. At
follow-up, both groups had better scores on all SF-36 scales
(with statistically significant improvement in social functioning
and mental health in group BPT), and all Skindex-29 scales had
lower values than those at baseline (Fig. 1). BPT patients who
reached a SAPASI-50 after the intervention had statistically
significant improvement in 5 scales of SF-36 health status
questionnaire (RP, VT, SF, RE, MH) compared to the baseline;
such improvement was not observed in patients treated only
with BT (Fig. 2).
Referring to what we defined as “warnings” from the items
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RESULTSof the Skindex-29 questionnaire, only one third of patients who
answered that she/he experienced that problem “all the time” at
baseline, still had the same problem 2 months after the end of
treatment. Especially in the symptom scale for items related to
“itch”, “irritation”, “skin sensitive”, a dramatic reduction was
observed in both groups.
GHQ-12 cases were reduced to 14% in the BPT group and to
18% in the BT group at the 2-month follow-up. The reduction
of GHQ-12 cases in BPT was statistically significant, while it
was not in BT.
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Table 2. Characteristic of Patients Treated with Balneophototherapy or Balneotherapy
BPT  (n. 66) BT  (n. 45)
No. % No. %
Sex
Male 42 63.6 25 55.6
Female 24 36.4 20 44.4
Age
< 50 yy 38 59.4 16 35.6
≥50 yy 26 40.6 29 64.4
Smoke
Yes 26 40.6 9 20.5
No 38 59.4 35 79.5
Alcool
Yes 8 12.5 10 22.7
No 56 87.5 34 77.3
Familiarity
Yes 28 45.2 20 45.5
No 34 54.8 24 54.5
Duration of disease
≤ 10 yy 13 20.9 12 27.3
> 10 yy 49 79.1 32 72.7
Phototype
I-II 24 37.5 24 54.6
III-IV 40 62.5 20 45.4
BMI  ≥ 25
Yes 32 50.8 28 63.6
No 31 49.2 16 36.4
GHQ-12 Cases 21 31.8 10 22.2
BMI, body mass index; GHQ-12, General Health Questionnaire-12.
Mean age years ±SD: BPT, balneophototherapy group (45.4 ±13.4), BT, balneotherapy group (55.4 ±14.8). 
Fig. 1. Skindex-29 test and SF-36 scales before and after BPT or BT therapies. SF-36, 36-item Short Form of the Medical Outcomes Study questionnaire; BTP,
balneophototherapy; BT, balneotherapy, PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role-emotional;
MH, mental health.
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Baseline Follow-upIn our study, we observed an improvement in clinical severity
of psoriasis and QoL in both groups of patients using Narrow-
Band UVB plus Comano spa water or Comano spa water
alone.
The design of our observational study did not include
randomisation, so that patients started one of the treatments on
basis of personal preference or indication. Thus, it is not
surprising that the 2 groups at baseline were quite different, and
that significant differences were observed for some of the most
relevant variables. BPT patients were younger with higher
mean SAPASI scores before treatment, and a higher proportion
of GHQ-12 cases. Such differences, in addition to very likely
differences in other unmeasured (or unmeasurable) factors, can
scarcely be appropriately taken care of even in a careful statis-
tical analysis, so that relevant residual biases should be
expected. Accordingly, it would be inappropriate to compare
the 2 treatments and to draw any conclusion about their relative
merits. However, it is interesting to describe within-group
changes between baseline and follow-up, since the resulting
estimates should be unbiased. 
It seems that Comano bath treatment per se has a relevant
effect on reducing SAPASI scores. In fact, a relevant reduction
was observed also in the group not involved with phototherapy,
since approximately 40% of reduction was reached in both
groups. Such reduction was present 2 months after the end of
treatment for both groups, during which period no other
treatment was administered except emollients, suggesting that
the effects of these interventions are not as ephemeral as they
are thought to be, but may persist for a significant lapse of time. 
The proportion of GHQ-12 positive patients in the BPT
group was statistically significantly reduced 2 months after the
intervention. We have recently observed in the prospective
section of the IMPROVE study
18 that improvement in
psychological well being is much more likely in patients with
higher percentages of reduction in SAPASI scores, and
therefore, the greater clinical improvement in BTP patients,
who had worse baseline SAPASI scores, could be a reason for
such reduction in psychosocial distress. 
Many patients with psoriasis request alternative therapies and
BPT or BT seem to be acceptable choices. Narrow-Band ultra-
violet B phototherapy is increasingly used as a treatment for
psoriasis and the association with balneotherapy was introduced
especially with saline bath water.
19,20
The beneficial effect of bathing before UVB exposure could
be partially explained by the fact that desquamation and
reduction of thickness of lesional skin cause a decrease in the
barrier function against irradiation.
21 Another mechanism for
salt water bath is that skin erythemal sensitivity can be
increased. Bathing in high-concentration salt solution might
enhance the effectiveness of UVB phototherapy, psoriasis
lesional skin shows an increase of human leucocites elastasy
activity compared with unaffected skin and its increased
activity contributes to the persistence of psoriasic lesions. High
concentration salt solution can elute this enzyme from psoriasic
skin and its reduction can improve psoriasis.
22,23 Contradictory
data are present in the literature about the use of salt water and
UVB. Non randomised comparison studies on patients with
psoriasis support the common notion that there is a beneficial
effect of salt water bath prior to phototherapy.
24,25 Data obtained
from comparative studies suggest that any additional benefits of
soaking in salt water and tap water in BPT are unlikely to be
due to the salinity of the liquids.
26
A French group published an observed-blinded, 3-arm
randomised control trial (RCT) comparing saline spa water bath
alone, spa water bath plus Narrow-Band, UVB and UVB
monotherapy in 71 patients with psoriasis, and concluded that
spa water bath alone had a minor therapeutic effects on
psoriasis, but the beneficial effect of bathing to enhance
phototherapy was not demonstrated.
6 In a recent randomised
study to evaluate the efficacy of Dead Sea salt balneotherapy
vs. narrow band ultraviolet B monotherapy for chronic plaque
psoriasis, Dawe et al.
7 reported that pre-treatment of Dead sea
salt soaks before administration of UVB did not result in a
clinically important improvement in clearance of psoriasis.
The chemical composition of water used for bathing could
catalyse and magnify the effect of phototherapy. BT with
Comano spa water is used for psoriasis and other skin disorders,
however the mechanism of action of this hypotonic water is still
unknown. Studies have demonstrated that Comano water
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Fig. 2. SF-36 scales before and after BPT or BP therapies in patients with reduction
of SAPASI > 50%. SF-36, 36-item Short Form of the Medical Outcomes Study
questionnaire; BTP, balneophototherapy; BT, balneotherapy, SAPASI, self-
administered Psoriasis Area Severity Index; PF, physical functioning; RP, role-
physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE,
role-emotional; MH, mental health.interferes with the expression and secretion of vascular endo-
thelial growth factor-A (VEGF-A) protein isoform in vitro.
These effects would reduce all VEGF-A-mediated angiogenic,
vessel permeabilising and chemotactic effects, explaining at
least in part the beneficial action of balneotherapy in clinical
manifestation of psoriasis.
27
We observed a reduction of SAPASI scores, an improvement
in QoL and overall health status in patients treated in Comano.
Even though the reduction of SAPASI scores is larger in the
group treated with UVB, the different baseline status in this
group should be taken into account, and the greater improve-
ment of skin conditions should not be attributed to the addition
of UVB to spa water alone. 
The improvement in QoL for psoriasis after BPT or BT
treatments was present in all dimensions explored by the
Skindex-29, i.e., emotional status, symptoms, and functioning.
The difference between before and after treatment did not reach
statistical significance, but was clinically relevant in both
groups. Especially for symptoms, the percentage of patients
experiencing a problem “all the time” was dramatically
reduced. The hypotonic Comano water certainly did not
increase itch or skin burning, as otherwise reported by Labreze
for a study on saline baths.
We wish to further acknowledge and actually warn the
readers on the limitations of our observational study: the
allocation to the therapeutic interventions was not randomised,
and we think that it is a good example of how non-random
allocation to different treatment groups often leads to baseline
differences that may heavily bias between-treatment compari-
sons. Furthermore, the use of postal questionnaires in the
follow-up did not guarantee feedback from all patients:
although percentages of response above 80% are excellent for
an observational study of this kind, they would be considered
scarce for a clinical trial. 
However, in conclusion, our study showed that BT with
hypotonic spa water, with or without additional UVB therapy,
had a beneficial effect on the clinical improvement of psoriasis.
Even considering the limitations of our study design, the
association of phototherapy with balneotherapy seems to have
effects on psoriasis similar the water bath alone. Information
obtained from this observational study might increase interest
towards evidence-based evaluation of balneotherapy and
balneophototherapy as treatments for psoriasis, and could
stimulate randomised controlled trials to test the relative efficacy
of the 2 treatments, as well as their possible long-term efficacy.
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